NCT03026933已完成3 期
A Multi-center, Randomized, Double Blind, Parallel Phase III Study to Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled
Kuhnil Pharmaceutical Co., Ltd.0 个研究点目标入组 215 人开始时间: 2014年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 215
- 主要终点
- Variation rate of Non HDL-C
研究概览
简要总结
To examine variation rate of Non-HDL with KI1107 comparison Rosuvastatin monotherapy.
详细描述
Study design:
Randomly assigned to two groups(KI1107 or Rosuvastatin monotherpy) after 4 weeks run-in period and prescribed KI1107 or Rosuvastatin for 8 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 19 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Treatment
Experimental
KI1107
干预措施: KI1107 4 Capsules, QD (Drug)
Control
Active Comparator
Rosuvastatin calcium
干预措施: Rosuvastatin Calcium 20 MG, QD (Drug)
结局指标
主要结局
Variation rate of Non HDL-C
时间窗: 8 weeks
次要结局
- Variation rate of Non HDL-C(4 weeks)
- Variation rate of TC(4 weeks, 8 weeks)
- Variation rate of TG(4 weeks, 8 weeks)
- Variation rate of LDL-C(4 weeks, 8 weeks)
- Variation rate of VLDL-C(4 weeks, 8 weeks)
- Variation rate of Apo A-I(4 weeks, 8 weeks)
- Variation rate of Apo B(4 weeks, 8 weeks)
研究者
相似试验
已完成
3 期
Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly ControlledDyslipidemiasNCT03482180Kuhnil Pharmaceutical Co., Ltd.215
已完成
3 期
Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 WeeksHypercholesterolemiaCoronary Heart DiseaseNCT00653588AstraZeneca
已完成
3 期
Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)HypercholesterolemiaNCT00090298Organon and Co2,815
招募中
不适用
Steroid Sparing in Immune Related Hepatitis (irH)Hepatitis ImmuneNCT05345847AHS Cancer Control Alberta56
已完成
3 期
Eze/Simva Switch Study in Diabetics (0653A-807)Diabetes Mellitus, Type 2NCT00541697Organon and Co648